candesartan and oxytetracycline, anhydrous

candesartan has been researched along with oxytetracycline, anhydrous in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's1 (25.00)24.3611
2020's2 (50.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Ma, C; Wang, J1
Huang, YY; Li, Z; Lin, Y; Liu, R; Luo, HB; Wang, X; Zhan, CG1

Reviews

1 review(s) available for candesartan and oxytetracycline, anhydrous

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

3 other study(ies) available for candesartan and oxytetracycline, anhydrous

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2021, 02-23, Volume: 118, Issue:8

    Topics: Acetates; Atazanavir Sulfate; Benzimidazoles; Biphenyl Compounds; Chloroquine; COVID-19 Drug Treatment; Cyclopropanes; Dipyridamole; Humans; Oxytetracycline; Pharmaceutical Preparations; Protease Inhibitors; Quinolines; SARS-CoV-2; Sulfides; Tetrazoles

2021
Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2021, 02-23, Volume: 118, Issue:8

    Topics: Acetates; Atazanavir Sulfate; Benzimidazoles; Biphenyl Compounds; Chloroquine; COVID-19 Drug Treatment; Cyclopropanes; Dipyridamole; Humans; Oxytetracycline; Protease Inhibitors; Quinolines; Reproducibility of Results; SARS-CoV-2; Sulfides; Tetrazoles

2021